Special Drug Use Survey of HERNICORE 1.25 units for intradiscal injection in Patients with Lumbar Disc Herniation

Special Drug Use Survey of HERNICORE 1.25 units for intradiscal injection in Patients with Lumbar Disc Herniation - HERNICORE Special Drug Use Survey

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034724

Enrollment

3000

Registered

2018-11-01

Start date

2019-02-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Disc Herniation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who were registered in the HERNICORE General Drug Use Survey

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Safety - Occurrence of adverse events and adverse reactions - Occurrence of post-treatment surgery for lumbar spinal instability at the same level of administration of HERNICORE Efficacy - Improvement of leg pain and low back pain - Occurrence of post-treatment surgery for lumbar disc herniation at the same level of administration of HERNICORE - Global assessment (physician) - Effects on long-term prognosis (e.g., recurrence of herniation, osteophyte formation, spinal canal stenosis)	—

Measure

Time frame

Safety - Occurrence of adverse events and adverse reactions - Occurrence of post-treatment surgery for lumbar spinal instability at the same level of administration of HERNICORE Efficacy - Improvement of leg pain and low back pain - Occurrence of post-treatment surgery for lumbar disc herniation at the same level of administration of HERNICORE - Global assessment (physician) - Effects on long-term prognosis (e.g., recurrence of herniation, osteophyte formation, spinal canal stenosis)

—

Countries

Japan

Contacts

Public ContactKazuki Endo

SEIKAGAKU CORPORATION Pharmacovigilance Dept.

HER_GPSP_2_SKK@seikagaku.co.jp03-5220-8556

Outcome results